Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
| ▸ | SIK2 | Q9H0K1 | 3/20 | 0.34 |
| ▸ | SIK1 | P57059 | 2/20 | 0.34 |
| ▸ | SIK3 | Q9Y2K2 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | STK3 | Q13188 | 1/20 | 0.34 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.34 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22387812 | 0.88 | LMNA (0.40) | KMT2AMEN1RAB9AMAPTL3MBTL1 | |
| SCHEMBL4200763 | 0.85 | GRK6 (0.42) | KMT2AMEN1RAB9AMTNR1AMTNR1B | |
| SCHEMBL18969554 | 0.81 | KMT2A (0.41) | KMT2AMTNR1AMTNR1BPTGS2MAPT | |
| SCHEMBL2723333 | 0.80 | STK17B (0.48) | KMT2AMEN1MTNR1AMTNR1B | |
| SCHEMBL29437371 | 0.80 | STK17B (0.48) | KMT2AMEN1MTNR1AMTNR1B | |
| SCHEMBL19301507 | 0.78 | KMT2A (0.36) | KMT2AMEN1RAB9AMTNR1AMTNR1B | |
| SCHEMBL4200756 | 0.76 | KMT2A (0.38) | KMT2AMEN1RAB9AMAPTNPSR1 | |
| SCHEMBL18493988 | 0.75 | PIK3CA (0.32) | PAK1SIK2SIK1SIK3PIK3CA | |
| SCHEMBL22554008 | 0.74 | MAPT (0.38) | KMT2AMEN1RAB9AMAPTL3MBTL1 | |
| SCHEMBL2723630 | 0.74 | CCR9 (0.41) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | G1 THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20220175780-A1 | TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS | PHARMACOSMOS A/S (DK) | 2022-06-09 | — | — | US | disclosed |
| US-20140142299-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142299-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142306-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142306-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20130237544-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237534-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237544-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237533-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237534-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2012061156-A1 | CDK INHIBITORS | TAVARES FRANCIS X (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237534-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | KMT2A 276/4885MEN1 2275/4885RAB9A 2036/4885 |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | RB1, CDK4, CDKN1A | KMT2A 117/4885MEN1 3437/4885RAB9A 2448/4885 |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | MKI67, PCNA, HRAS | KMT2A 1098/4885MEN1 455/4885RAB9A 2970/4885 |
| US-20220175780-A1 | TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS | RB1, CDK4, CDK6 | KMT2A 757/4885MEN1 3291/4885RAB9A 2394/4885 |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CDK6, CCNC, MCL1 | KMT2A 513/4885MEN1 3666/4885RAB9A 3450/4885 |
| US-20140142306-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | KMT2A 276/4885MEN1 2275/4885RAB9A 2036/4885 |
| US-20130237533-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | KMT2A 276/4885MEN1 2275/4885RAB9A 2036/4885 |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | CDK4, RB1, BTK | KMT2A 838/4885MEN1 1943/4885RAB9A 1815/4885 |
| US-20140142299-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | KMT2A 276/4885MEN1 2275/4885RAB9A 2036/4885 |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | RB1, CDK4, CDKN1A | KMT2A 117/4885MEN1 3437/4885RAB9A 2448/4885 |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | KMT2A 513/4885MEN1 3666/4885RAB9A 3450/4885 |
| US-20130237544-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | KMT2A 276/4885MEN1 2275/4885RAB9A 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.